REGENXBIO, Inc. (RGNX)
8.53
-0.03
(-0.35%)
USD |
NASDAQ |
Sep 11, 16:00
8.52
-0.01
(-0.12%)
After-Hours: 20:00
REGENXBIO Enterprise Value : 606.74M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 606.74M |
| September 10, 2026 | 608.36M |
| September 09, 2026 | 617.57M |
| September 08, 2026 | 619.20M |
| September 04, 2026 | 628.95M |
| September 03, 2026 | 643.03M |
| September 02, 2026 | 664.69M |
| September 01, 2026 | 649.53M |
| August 31, 2026 | 659.28M |
| August 28, 2026 | 667.94M |
| August 27, 2026 | 652.24M |
| August 26, 2026 | 652.78M |
| August 25, 2026 | 627.32M |
| August 24, 2026 | 581.01M |
| August 21, 2026 | 725.36M |
| August 20, 2026 | 743.77M |
| August 19, 2026 | 795.77M |
| August 18, 2026 | 744.32M |
| August 17, 2026 | 758.40M |
| August 14, 2026 | 727.80M |
| August 13, 2026 | 722.11M |
| August 12, 2026 | 735.65M |
| August 11, 2026 | 721.57M |
| August 10, 2026 | 709.11M |
| August 07, 2026 | 725.36M |
| Date | Value |
|---|---|
| August 06, 2026 | 755.69M |
| August 05, 2026 | 713.44M |
| August 04, 2026 | 702.61M |
| August 03, 2026 | 684.19M |
| July 31, 2026 | 669.57M |
| July 30, 2026 | 692.86M |
| July 29, 2026 | 665.78M |
| July 28, 2026 | 664.69M |
| July 27, 2026 | 670.65M |
| July 24, 2026 | 671.74M |
| July 23, 2026 | 699.90M |
| July 22, 2026 | 697.19M |
| July 21, 2026 | 704.78M |
| July 20, 2026 | 703.69M |
| July 17, 2026 | 680.40M |
| July 16, 2026 | 751.36M |
| July 15, 2026 | 809.31M |
| July 14, 2026 | 810.40M |
| July 13, 2026 | 835.31M |
| July 10, 2026 | 900.31M |
| July 09, 2026 | 992.39M |
| July 08, 2026 | 969.64M |
| July 07, 2026 | 958.26M |
| July 06, 2026 | 947.97M |
| July 02, 2026 | 864.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 518.65B |
| Capricor Therapeutics, Inc. | 339.48M |
| United Therapeutics Corp. | 18.55B |
| Ardelyx, Inc. | 866.31M |
| Biomea Fusion, Inc. | 91.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 22.71M |
| Revenue (Quarterly) | 108.02M |
| Total Expenses (Quarterly) | 85.31M |
| EPS Diluted (Quarterly) | 0.4283 |
| Gross Profit Margin (Quarterly) | 95.56% |
| Profit Margin (Quarterly) | 21.02% |
| Earnings Yield | -44.37% |
| Normalized Earnings Yield | -44.37 |